In vitro and in vivo evaluation of novel chromeno[2,3-d]pyrimidinones as therapeutic agents for triple negative breast cancer

被引:0
作者
Carvalho, Luisa [1 ,2 ]
de Lima, Fabio Pedroso [3 ]
Cerqueira, Monica [1 ,2 ]
Silva, Ana [1 ,2 ]
Pontes, Olivia [1 ,2 ]
Oliveira-Pinto, Sofia [1 ,2 ]
Guerreiro, Sara [1 ,2 ,4 ]
Costa, Marta D. [1 ,2 ]
Granja, Sara [1 ,2 ,4 ]
Maciel, Patricia [1 ,2 ]
Longatto-Filho, Adhemar [1 ,2 ,5 ,6 ]
Baltazar, Fatima [1 ,2 ]
Proenca, Fernanda [3 ]
Costa, Marta [1 ,2 ]
机构
[1] Univ Minho, Life & Hlth Sci Res Inst ICVS, Campus Gualtar, Braga, Portugal
[2] ICVS 3Bs PT Govt Associate Lab, Braga Guimaraes, Portugal
[3] Univ Minho, Dept Chem, Campus Gualtar, Braga, Portugal
[4] Polytech Inst Porto, Sch Hlth, Dept Pathol Cytolog & Thanatol Anat, P-4200072 Porto, Portugal
[5] Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil
[6] Univ Sao Paulo, Med Sch, Dept Pathol, Med Lab Med Invest LIM 14, Sao Paulo, Brazil
来源
RSC MEDICINAL CHEMISTRY | 2024年 / 15卷 / 04期
关键词
C-ELEGANS; MODEL; EXPRESSION; APOPTOSIS; TARGETS; MOUSE; CELLS;
D O I
10.1039/d3md00682d
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, and the limited therapeutic options show poor efficacy in patients, associated to severe side effects and development of resistance. Considering that chromene-based scaffolds proved to be attractive candidates for cancer therapy, herein we prepared new chromeno[2,3-d]pyrimidinone derivatives by a simple two step procedure, starting from the reaction of cyanoacetamide and a salicylaldehyde. A cell viability screening in several breast cancer cell lines allowed to identify two promising compounds with IC50 values in the low micromolar range for TNBC cells. These chromenes inhibited cell proliferation, induced cell cycle arrest and triggered cell death through apoptosis. In vivo studies revealed a safe profile in invertebrate and vertebrate animal models and confirmed their capacity to inhibit tumor growth in the CAM model, inducing significant tumor regression after 4 days of treatment. The two compounds identified in this study are promising drug candidates for TNBC treatment and valuable hits for future optimization, using the versatile synthetic platform that was developed.
引用
收藏
页码:1362 / 1380
页数:19
相关论文
共 50 条
  • [21] Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro
    Garcia-Quiroz, Janice
    Cardenas-Ochoa, Nohemi
    Garcia-Becerra, Rocio
    Morales-Guadarrama, Gabriela
    Mendez-Perez, Edgar A.
    Santos-Cuevas, Clara
    Ramirez-Nava, Gerardo J.
    Segovia-Mendoza, Mariana
    Prado-Garcia, Heriberto
    Avila, Euclides
    Larrea, Fernando
    Diaz, Lorenza
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2021, 214
  • [22] NOVEL PYRIDO[2,3-d]PYRIMIDINE AND QUINAZOLINE DERIVATIVES AS CYTOTOXIC AGENTS IN SEVERAL CANCER CELL LINES
    Moreno, Esther
    Plano, Daniel
    Font, Maria
    Antonio Palop, Juan
    Calvo, Alfonso
    Encio, Ignacio
    Sanmartin, Carmen
    DRUGS OF THE FUTURE, 2009, 34 : 109 - 109
  • [23] Evaluation of N-aryl-β-alanine derivatives as anticancer agents in triple-negative breast cancer and glioblastoma in vitro models
    Zukauskas, Mindaugas
    Grybaite, Birute
    Jonute, Paulina
    Vaickelioniene, Rita
    Gibiez, Paulius
    Vaickelionis, Giedrius
    Dragunaite, Bertina
    Anusevicius, Kazimieras
    Mickevicius, Vytautas
    Petrikaite, Vilma
    BIOORGANIC CHEMISTRY, 2021, 115
  • [24] Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
    Jin, Juan
    Fang, Hehui
    Yang, Fang
    Ji, Wenfei
    Guan, Nan
    Sun, Zijia
    Shi, Yaqin
    Zhou, Guohua
    Guan, Xiaoxiang
    NEOPLASIA, 2018, 20 (05): : 478 - 488
  • [25] Discovering alkylamide derivatives of bexarotene as new therapeutic agents against triple-negative breast cancer
    Chen, Luxi
    Long, Chao
    Nguyen, Jennifer
    Kumar, Dhiraj
    Lee, Jiyong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (03) : 420 - 424
  • [26] Isobavachalcone, a natural sirtuin 2 inhibitor, exhibits anti-triple-negative breast cancer efficacy in vitro and in vivo
    Ren, Ya-li
    Lei, Jie-ting
    Zhang, Ting-rui
    Lu, Peng
    Cui, Dan-dan
    Yang, Bo
    Zhao, Gui-ying
    Peng, Fu
    Cao, Zhi-xing
    Peng, Cheng
    Li, Yu-zhi
    PHYTOTHERAPY RESEARCH, 2024, 38 (04) : 1815 - 1829
  • [27] Shikonin is a novel and selectiveIMPDH2inhibitor that target triple-negative breast cancer
    Wang, Wanyan
    Wu, Yu
    Chen, Si
    Liu, Xi
    He, Jiacheng
    Wang, Shuyi
    Lu, Weiqiang
    Tang, Yong
    Huang, Jin
    PHYTOTHERAPY RESEARCH, 2021, 35 (01) : 463 - 476
  • [28] Cold atmospheric plasma conveys selectivity on triple negative breast cancer cells both in vitro and in vivo
    Xiang, Liangjian
    Xu, Xiaoyu
    Zhang, Shuo
    Cai, Dongyan
    Dai, Xiaofeng
    FREE RADICAL BIOLOGY AND MEDICINE, 2018, 124 : 205 - 213
  • [29] Natural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo
    Gou, Leilei
    Yue, Grace Gar-Lee
    Lee, Julia Kin -Ming
    Puno, Pema Tenzin
    Lau, Clara Bik-San
    BIOCHEMICAL PHARMACOLOGY, 2023, 210
  • [30] Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer
    Kalscheuer, Stephen
    Khanna, Vidhi
    Kim, Hyunjoon
    Li, Sihan
    Sachdev, Deepali
    DeCarlo, Arthur
    Yang, Da
    Panyam, Jayanth
    SCIENTIFIC REPORTS, 2019, 9 (1)